Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-25

Study Completion Date

2022-04-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation, Acute respiratory distress syndrome (ARDS), requirement for supplemental oxygenation, artificial ventilation or death in patients with COVID-19 on supplemental oxygen.

\* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Defibrotide for the Treatment of Severe COVID-19

NCT04652115

Covid19

RECRUITING PHASE2

Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

NCT04634799

Covid19

SUSPENDED PHASE1/PHASE2

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

NCT04705597

Covid19

TERMINATED PHASE2

Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19

NCT04928430

COVID-19

TERMINATED PHASE2/PHASE3

Study of Varespladib in Patients Hospitalized With Severe COVID-19

NCT04969991

Coronavirus Disease 2019 Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zavegepant

Zavegepant (BHV-3500) 10 mg intranasal (IN) dosed every 8 hours (3 times/day) (Q8h) for 14 days

Group Type EXPERIMENTAL

Zavegepant (BHV-3500)

Intervention Type DRUG

10 mg intranasal (IN) for 14 days

Placebo

Placebo Q8h for 14 days

Subjects dosed every 8 hours; 3 times/day (Q8h)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo Q8h for 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zavegepant (BHV-3500)

10 mg intranasal (IN) for 14 days

Intervention Type DRUG

Placebo

Placebo Q8h for 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects must provide informed consent in accordance with requirements of the study center's institutional review board (IRB) or eithics committee prior to the initiation of any protocol-required procedures
2. Subjects must agree to provide all requested demographic information (i.e. gender, race)
3. Subjects must be able to read and understand English or Spanish
4. Subjects must be over the age of 18 years
5. Subjects must have laboratory-confirmed SARS-CoV-2 infection as determined by PCR-based commercial or public health assay
6. Subjects must have symptoms that require hospitalization with supplemental oxygen and / or non-invasive ventilation as determined by the admitting physician. The maximum nasal cannula O2 concentration should be determined by the treating clinician and the limitations of the specific equipment
7. Subjects must be willing and able to comply with study-related procedures/assessments

Exclusion Criteria

1. Subjects in immediate need of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
2. Subjects with an eGFR \< 30 mL/min, at the Screening Visit
3. Prisoners or subjects who are involuntarily incarcerated
4. Subjects who are participating in any other investigational clinical trial while participating in this clinical trial
5. Subjects who are under the age of 18 years
6. Subjects who are pregnant (all potential female enrollees need to have a negative pregnancy test prior to IP administration)
7. Subjects with multi-organ failure
8. Subjects who have received more than 48 hours of supplemental oxygen prior to randomization
9. Subjects with prior significant pulmonary disease (e.g., severe COPD/ILD/CHF/IPF) are excluded
10. Subjects receiving investigational therapies as part of a formal clinical trial for the treatment of COVID-19. During the course of this study, investigational therapies that may become "standard of care" to treat COVID-19, but are not part of a clinical trial, are allowed
11. Subjects who are on long-acting CGRP monoclonal antibodies will be excluded including Aimovig (erenumab), Emgality (galcanezumab), Ajovy (fremanezumab), and Vyepti (eptinezumab). Additionally, the investigational oral CGRP receptor antagonist, atogepant, that is taken daily will also be excluded. Oral CGRP receptor antagonists, Nurtec ODT (rimegepant) and Ubelvy (ubrogepant) that are typically used PRN infrequently will not be excluded as long the subject was not taking them on a daily basis and does not take them during the current study
12. Subjects who are unlikely to survive for more than 48 hours from the Screening Visit
13. Subjects with any of the following abnormal laboratory values at screening: aspartate AST or ALT greater than 5x ULN or bilirubin greater than 2x ULN
14. Subjects with known active TB, history of incompletely treated TB, suspected or known extrapulmonary TB
15. Subjects with suspected or known systemic bacterial or fungal infections. However, empiric antibiotics are permitted.
16. Subjects who have participated in any clinical research study evaluating an IP or therapy within 3 months and less than 5 half-lives of IP prior to the screening visit
17. Subjects with any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by their participation in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No